Coding Lysosomal Storage Disorders: A Reference Guide for Inpatient Coders
Lysosomal storage disorders are a group of rare, inherited metabolic conditions mainly caused by genetic mutations which disrupt normal lysosome function. Lysosomes are cell’s recycling centers — they house the enzymes responsible for breaking down fats, sugars, proteins & other cellular material. When one of the enzymes is missing, deficient, or not working properly, the substance it’s supposed to process builds up inside the cell instead. Over time, that accumulation damages tissue and organ function, sometimes progressively and sometimes quite rapidly depending on the disorder.
Because these conditions can affect any organ system — nervous system, heart, liver, spleen, bones, kidneys, blood, or several at once — there’s no single catch-all ICD-10-CM code for “lysosomal storage disorder.” The correct code always depends on the specific metabolic disorder which the provider has documented, which means coders working these charts need a working knowledge of the major disease categories rather than a single memorized code.
This overview walks through the major categories inpatient coders are most likely to encounter, along with the coding nuances that tend to trip people up. As with any rare or genetically complex diagnosis, the rule that governs everything here is the same one that applies across inpatient coding generally: code to the most specific diagnosis actually documented, and never conclude on a subtype from clinical findings alone.
Glycogen Storage Diseases
Glycogen storage diseases (GSD) involve the body’s inability to properly store or break down glycogen, the storage form of glucose. Not every GSD is a lysosomal disorder, this is one of the important note coders need to make. Pompe disease is the best-known lysosomal example, caused by a deficiency of acid alpha-glucosidase (acid maltase), which lets glycogen accumulate inside lysosomes, primarily affecting skeletal and cardiac muscle. Presentation ranges from severe infantile disease with cardiac involvement to milder, later-onset forms affecting skeletal and respiratory muscles.
By contrast, von Gierke disease — a glucose-6-phosphatase deficiency responsible for roughly a quarter of all GSD cases — is not a lysosomal disorder at all. It prevents glucose from being released from glycogen properly, leading to accumulation mainly in the liver & kidneys, along with significant hypoglycemia.
GSDs are divided into types 0 through XI, but not every type has its own unique code. Several are grouped under E74.09 (other glycogen storage disease), including type 0 (Lewis’ disease), type IV (Andersen’s disease), type VI (Hers’ disease), type VII (Tarui’s disease), type IX (phosphorylase kinase deficiency), and type XI (Fanconi-Bickel syndrome). The remaining types have dedicated codes:
- E74.01 — von Gierke disease (type I)
- E74.02 — Pompe disease (type II), includes cardiac glycogenosis
- E74.03 — Cori disease (type III), includes Forbes disease
- E74.04 — McArdle disease (type V)
The key documentation distinction to watch for: Pompe disease is lysosomal, while Cori disease and McArdle disease are not, even though all three sit under the same GSD umbrella.
Gangliosidosis
Gangliosidoses result from deficient lysosomal enzymes that fail to break down gangliosides — complex lipids concentrated in cell membranes. Clinical presentation is typically progressive neurologic dysfunction, appearing anywhere from infancy through adulthood depending on residual enzyme activity.
GM2 gangliosidoses — the category that includes Tay-Sachs disease and Sandhoff disease — carry these codes:
- E75.00 — GM2 gangliosidosis, unspecified
- E75.01 — Sandhoff disease
- E75.02 — Tay-Sachs disease
- E75.09 — Other GM2 gangliosidosis (includes adult and juvenile forms)
Other gangliosidosis types include:
- E75.10 — Unspecified gangliosidosis (includes gangliosidosis NOS)
- E75.11 — Mucolipidosis IV (sometimes grouped here despite not being a true gangliosidosis)
- E75.19 — Other gangliosidosis (includes GM1 and GM3 gangliosidosis)
Sphingolipidosis
This is a broad category involving accumulation of sphingolipids — key components of cell membranes — due to deficient degradation enzymes. Manifestations vary widely by disorder and can involve the nervous system, blood, kidneys, heart, skeleton, or internal organs. Fabry disease, Gaucher disease, Krabbe disease, and Niemann-Pick disease all fall under this category:
- E75.21 — Fabry (-Anderson) disease
- E75.22 — Gaucher disease
- E75.23 — Krabbe disease
- E75.240 — Niemann-Pick disease type A (includes ASMD type A, infantile neurovisceral ASMD)
- E75.241 — Niemann-Pick disease type B (includes ASMD type B, chronic visceral ASMD)
- E75.242 — Niemann-Pick disease type C
- E75.243 — Niemann-Pick disease type D
- E75.244 — Niemann-Pick disease type A/B (includes ASMD type A/B, chronic neurovisceral ASMD)
- E75.249 — Niemann-Pick disease, unspecified (includes ASMD NOS)
- E75.25 — Metachromatic leukodystrophy
- E75.26 — Sulfatase deficiency (includes multiple sulfatase deficiency)
- E75.27 — Pelizaeus-Merzbacher disease
- E75.28 — Canavan disease
- E75.29 — Other sphingolipidosis (includes Farber syndrome and sulfatide lipidosis)
Niemann-Pick disease is a textbook example of why chasing full specificity matters: five distinct subtype codes exist, and defaulting to “unspecified” when the documentation could support more detail undersells the record. If the subtype isn’t clear from the chart, this is exactly the kind of gap worth a physician query rather than a guess — the same principle that applies to clarifying comorbidities and complications on any inpatient chart.
Mucopolysaccharidosis
Mucopolysaccharidoses (MPS) result from impaired breakdown of glycosaminoglycans (historically called mucopolysaccharides), leading to abnormalities across the skeleton, joints, connective tissue, heart, respiratory system, liver, spleen, and, in some forms, the central nervous system. Each MPS type traces back to a different enzyme deficiency:
- E76.0- — Mucopolysaccharidosis type I
- E76.01 — Hurler’s syndrome
- E76.02 — Hurler-Scheie syndrome
- E76.03 — Scheie’s syndrome
- E76.1 — Mucopolysaccharidosis type II (includes Hunter’s syndrome)
- E76.21- — Morquio mucopolysaccharidoses
- E76.210 — Morquio A (includes classic Morquio syndrome, MPS type IVA)
- E76.211 — Morquio B (includes Morquio-like MPS, MPS type IVB)
- E76.219 — Morquio mucopolysaccharidoses, unspecified (includes MPS type IV)
- E76.22 — Sanfilippo mucopolysaccharidoses (includes MPS type III, Sanfilippo A/B/C/D)
- E76.29 — Other mucopolysaccharidoses (includes beta-glucuronidase deficiency, Maroteaux-Lamy syndrome, MPS types VI and VII)
Documentation for MPS cases may use the syndrome eponym or the numbered type interchangeably, so coders should be comfortable moving between both — checking the Alphabetic Index for whichever term appears in the chart and confirming the final code selection in the Tabular List. One notable gap: MPS type IX (Natowicz syndrome) is exceedingly rare and currently has no dedicated code or coding guidance at all, so a query or use of an unspecified code may be your only option if it’s ever documented.
Disorders of Glycoprotein Metabolism
This category covers inherited disorders where glycoprotein processing or degradation goes wrong, leading to accumulation of partially degraded material and multisystem disease. These conditions tend to be less familiar simply because they’re rare and are often documented by disease-specific name rather than the broader metabolic category:
- E77.0 — Defects in post-translational modification of lysosomal enzymes (includes mucolipidosis II/I-cell disease and mucolipidosis III/pseudo-Hurler polydystrophy)
- E77.1 — Defects in glycoprotein degradation (includes aspartylglucosaminuria, fucosidosis, mannosidosis, and sialidosis/mucolipidosis I)
- E77.8 — Other disorders of glycoprotein metabolism
When one of these disease-specific names shows up in documentation, search on that term directly rather than trying to work backward from the general category.
A Coding Approach That Works Across All of These Categories
Given how many similarly-named conditions exist across these categories — GM2 gangliosidosis versus other gangliosidosis, the five Niemann-Pick subtypes, MPS eponyms versus numbered types — the safest approach is consistent: locate the exact term the provider used in the Alphabetic Index, verify it against the Tabular List, and never substitute a more general code when the documentation actually supports something more specific. Because these are frequently high-acuity inpatient admissions involving multiple organ systems, correct primary and secondary diagnosis selection also has real downstream effects on MS-DRG assignment and reimbursement, so it’s worth the extra minute to confirm the subtype before finalizing the chart.
Endocrine and metabolic disease coding, more broadly, continues to see periodic expansion in ICD-10-CM’s endocrine chapter and ongoing coding clinic guidance for Chapter 4 conditions, so it’s worth keeping an eye on annual updates even in this comparatively niche corner of the code set — new granularity tends to show up here as clinical understanding of these rare diseases improves.
